BW
NVO

Bravera Wealth’s Novo Nordisk NVO Stock Holding History

Bravera Wealth’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.8K Hold
121
– – ﹤0.01% 300
2026
Q1 		$4.45K Sell
121
-62
-34% -$2.94K ﹤0.01% 343
2025
Q4 		$9.31K Buy
+183
New +$9.36K ﹤0.01% 278

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Bravera Wealth's NVO Position: Q2 2026 in Review

Bravera Wealth held its Novo Nordisk (NVO) position steady in Q2 2026 at 121 shares worth $5.8K. The position accounts for ﹤0.01% of the portfolio, ranked #300.

Bravera Wealth first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.31K in Q4 2025. 397 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Bravera Wealth held 121 shares of Novo Nordisk worth $5.8K as of Q2 2026.
  • Bravera Wealth left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up ﹤0.01% of Bravera Wealth's portfolio in Q2 2026, its #300 holding.
  • Bravera Wealth first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
  • Bravera Wealth's Novo Nordisk position peaked at $9.31K in Q4 2025.
  • 397 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Bravera Wealth's 13F filing for Q2 2026, filed 23 Jul 2026.